[25-NSE] Y-mAbs Therapeutics, Inc. SEC Filing

Rhea-AI Filing Summary

Y-mAbs Therapeutics, Inc. submitted a Form 25 notification indicating the company’s class of securities will be removed from listing and/or registration on the Nasdaq Stock Market LLC. The filing identifies Nasdaq as the exchange and confirms that the Exchange and the Issuer have followed the procedural rules governing removal or voluntary withdrawal under the Securities Exchange Act. The document is a short procedural notice and does not include financial results, reasons for the removal, effective delisting date, or details about alternate trading arrangements.

Positive

• Procedural compliance confirmed with Nasdaq rules in filing
• Formal notice filed which clarifies regulatory status and starts the administrative process

Negative

• Securities will be removed from Nasdaq, reducing listing liquidity and visibility
• Filing lacks key details such as effective delisting date, reason for removal, and post-delisting trading plans

Insights

Capital Markets Specialist

Delisting notice filed; action is procedural and material to liquidity.

The filing records that Y-mAbs Therapeutics, Inc. will be removed from Nasdaq and that both the Exchange and the issuer complied with the procedural requirements for a Form 25 filing. This is a formal step that typically precedes or records removal from an exchange and affects where and how the shares trade.

Key dependencies include the effective delisting date and whether the removal is voluntary or enforcement-driven; those specifics are not present in the document. Monitor any subsequent filings for the effective date, transfer to OTC markets, or disclosures on shareholder rights over the next 30–90 days.

Corporate Governance Analyst

Procedural compliance confirmed; limited public detail in this notice.

The notice confirms compliance with Exchange rules under 17 CFR 240.12d2-2 subsections and cites procedural conformity for removal or voluntary withdrawal. It does not state operational, regulatory, or financial causes for the removal.

Investors should look for accompanying notices, proxy materials, or regulatory filings that explain the rationale and any board resolutions; expect additional disclosure within the issuer’s subsequent SEC filings or exchange notices within the near term.

UNITED STATES

OMB APPROVAL

OMB Number:			3235-0080
Expires:	March 31, 2018
Estimated average burden
hours per response:			1.7

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 25

NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION
UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission File Number

001-38650

Issuer:	Y-mAbs Therapeutics, Inc.
Exchange:	Nasdaq Stock Market LLC

(Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)

Address:	202 Carnegie Center, Suite 301
	Princetone	NEW JERSEY	08540
Telephone number:					646-885-8505

(Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)

Common Stock

(Description of class of securities)

Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:

17 CFR 240.12d2-2(a)(1)

17 CFR 240.12d2-2(a)(2)

17 CFR 240.12d2-2(a)(3)

17 CFR 240.12d2-2(a)(4)

Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. ¹

Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.

Pursuant to the requirements fo the Securities Exchange Act of 1934, Nasdaq Stock Market LLC certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.

2025-09-16	By	Jennifer Fainer		CDO Analyst
Date		Name		Title

¹ Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What does the Form 25 filing mean for Y-mAbs Therapeutics (YMAB)?

The Form 25 indicates YMAB's class of securities will be removed from listing and/or registration on Nasdaq; it is a procedural notice and does not state financial results or reasons.

Does the Form 25 state the effective date of delisting for YMAB?

No. The filing confirms procedural compliance but does not provide an effective delisting date.

Is the removal described as voluntary or involuntary in the filing?

The document references both Exchange and issuer compliance with withdrawal procedures but does not specify whether the removal is voluntary or enforcement-driven.

Will YMAB shares continue to trade after this filing?

The filing does not state post-delisting trading arrangements; typically shares may move to OTC markets, but no such plan is disclosed here.

Where can investors find more details about the delisting?

Investors should monitor subsequent SEC and Exchange filings for the effective date, rationale, and any plans for alternate trading venues.